11:06 AM EDT, 03/18/2024 (MT Newswires) -- Perspective Therapeutics ( CATX ) said Monday that it has entered into a clinical trial collaboration agreement with Bristol-Myers Squibb ( BMY ) for a melanoma combination study.

The study will assess the safety and tolerability of Perspective's targeted alpha-particle therapy plus Bristol-Myers' nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans, Perspective said.

Perspective said that under the agreement, it will sponsor and fund the combination study while Bristol-Myers will provide nivolumab.

The combination study is an amendment to Perspective's current phase 1/2a study of its targeted alpha-particle therapy in patients with metastatic melanoma, the company said.

Perspective shares slid 3.7% while Bristol-Myers shares were down 0.4% in recent trading.

Price: 52.14, Change: -0.20, Percent Change: -0.38